title: Prospects for prediction: ethics analysis of neuroimaging in Alzheimer's disease.
abstract: This article focuses on the prospects and ethics of using neuroimaging to predict Alzheimer's disease (AD). It is motivated by consideration of the historical roles of science in medicine and society, and considerations specifically contemporary of capabilities in imaging and aging, and the benefits and hope they bring. A general consensus is that combinations of imaging methods will ultimately be most fruitful in predicting disease. Their roll-out into translational practice will not be free of complexity, however, as culture and values differ in terms of what defines benefit and risk, who will benefit and who is at risk, what methods must be in place to assure the maximum safety, comfort, and protection of subjects and patients, and educational and policy needs. Proactive planning for the ethical and societal implications of predicting diseases of the aging brain is critical and will benefit all stakeholders-researchers, patients and families, health care providers, and policy makers.
authors.affiliation: Stanford Center for Biomedical Ethics and Department of Radiology, Program in Neuroethics, Stanford, California 94304-5748, USA. illes@stanford.edu
authors.forename: J
authors.initials: J
authors.lastname: Illes
authors.forename: A
authors.initials: A
authors.lastname: Rosen
authors.forename: M
authors.initials: M
authors.lastname: Greicius
authors.forename: E
authors.initials: E
authors.lastname: Racine
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000473:pathology*; D015415:Biomarkers; D003072:Cognition Disorders / Q000473:pathology; D003952:Diagnostic Imaging / Q000941:ethics*; D032984:Ethics, Research; D006801:Humans; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D018570:Risk Assessment
chemical_list: D015415:Biomarkers